Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

AKTX - Akari Therapeutics, Plc Последние новости | Finranks

Home

/

AKTX

A

Akari Therapeutics, Plc (AKTX)

NCM – Цена в реальном времени. Валюта: USD

3.06

-2.09 (-40.58%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancer Approval strengthens Akari's global intellectual property across all major markets and supports advancement of AKTX-101 and ADC pipeline

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at 5:00 PM ET TAMPA, Fla. and LONDON, April 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads, today announced that its abstract has been accepted for online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026.

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance Preclinical data support advancement of AKTX-101 into Phase 1 studies in a rapidly evolving TROP2 ADC class expected to reach ~$12B by 2033 1 TAMPA, Fla. and LONDON, April 20, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the presentation of positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, at the American Association for Cancer Research (AACR) Annual Meeting 2026.

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC

CEO Abizer Gaslightwala discusses the Company's strategic partnership with WuXi XDC and its implications for platform validation and development acceleration

Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026 Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17–22, 2026.

Видео

No Data

There is no data to display

Пресс-релизы

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets

Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload

Patent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancer Approval strengthens Akari's global intellectual property across all major markets and supports advancement of AKTX-101 and ADC pipeline

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at 5:00 PM ET TAMPA, Fla. and LONDON, April 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads, today announced that its abstract has been accepted for online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026.

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance Preclinical data support advancement of AKTX-101 into Phase 1 studies in a rapidly evolving TROP2 ADC class expected to reach ~$12B by 2033 1 TAMPA, Fla. and LONDON, April 20, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the presentation of positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, at the American Association for Cancer Research (AACR) Annual Meeting 2026.